Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Maria A. Pizzichetta is active.

Publication


Featured researches published by Maria A. Pizzichetta.


Archives of Dermatology | 2008

Dermoscopic Evaluation of Amelanotic and Hypomelanotic Melanoma

Scott W. Menzies; Juergen Kreusch; Karen Byth; Maria A. Pizzichetta; Ashfaq A. Marghoob; Ralph P. Braun; Josep Malvehy; Susana Puig; Giuseppe Argenziano; Iris Zalaudek; Harold S. Rabinovitz; Margaret Oliviero; Horacio Cabo; Verena Ahlgrimm-Siess; Michelle Avramidis; Pascale Guitera; H. Peter Soyer; Giovanni Ghigliotti; Masaru Tanaka; Ana Perusquia; Gianluca Pagnanelli; Riccardo Bono; Luc Thomas; Giovanni Pellacani; David Langford; Domenico Piccolo; Karin Terstappen; Ignazio Stanganelli; Alex Llambrich; Robert H. Johr

OBJECTIVE To determine the predictive dermoscopic features of amelanotic and hypomelanotic melanoma. DESIGN A total of 105 melanomas (median Breslow thickness, 0.76 mm), 170 benign melanocytic lesions, and 222 nonmelanocytic lesions lacking significant pigment (amelanotic, partially pigmented, and light colored) were imaged using glass-plate dermoscopy devices and scored for 99 dermoscopic features. Diagnostic models were derived from and tested on independent randomly selected lesions. SETTING Predominantly hospital-based clinics from 5 continents. MAIN OUTCOME MEASURES Sensitivity, specificity, and odds ratios for individual features and models for the diagnosis of melanoma and malignancy. RESULTS The most significant negative predictors of melanoma were having multiple (>3) milialike cysts (odds ratio, 0.09; 95% confidence interval, 0.01-0.64), comma vessels with a regular distribution (0.10; 0.01-0.70), comma vessels as the predominant vessel type (0.16; 0.05-0.52), symmetrical pigmentation pattern (0.18; 0.09-0.39), irregular blue-gray globules (0.20; 0.05-0.87), and multiple blue-gray globules (0.28; 0.10-0.81). The most significant positive predictors were having a blue-white veil (odds ratio,13; 95% confidence interval, 3.9-40.0), scarlike depigmentation (4.4; 2.4-8.0), multiple blue-gray dots (3.5; 1.9-6.4), irregularly shaped depigmentation (3.3; 2.0-5.3), irregular brown dots/globules (3.2; 1.8-5.6), 5 to 6 colors (3.2; 1.6-6.3), and predominant central vessels (3.1; 1.6-6.0). A simple model distinguishing melanomas from all nonmelanomas had a sensitivity of 70% and a specificity of 56% in the test set. A model distinguishing all malignant lesions from benign lesions had a sensitivity of 96% and a specificity of 37%. Conclusion Although the diagnostic accuracy of dermoscopy for melanoma lacking significant pigment is inferior to that of more pigmented lesions, features distinguishing the former from benign lesions can be visualized on dermoscopic evaluation.


British Journal of Dermatology | 2004

Amelanotic/hypomelanotic melanoma: clinical and dermoscopic features

Maria A. Pizzichetta; R. Talamini; I. Stanganelli; P. Puddu; R. Bono; Giuseppe Argenziano; A. Veronesi; G. Trevisan; H. Rabinovitz; H.P. Soyer

Background  Amelanotic malignant melanoma is a subtype of cutaneous melanoma with little or no pigment on visual inspection. It may mimic benign and malignant variants of both melanocytic and nonmelanocytic lesions.


British Journal of Dermatology | 2004

Dermoscopy of Bowen's disease.

Iris Zalaudek; Giuseppe Argenziano; B. Leinweber; L. Citarella; Rainer Hofmann-Wellenhof; J. Malvehy; Susana Puig; Maria A. Pizzichetta; L. Thomas; H.P. Soyer; H. Kerl

Background  Dermoscopy improves the diagnostic accuracy in pigmented skin lesions, but it is also useful in the evaluation of nonpigmented skin tumours as it allows the recognition of vascular structures that are not visible to the naked eye. Bowens disease (BD) or squamous cell carcinoma in situ is usually nonpigmented, but may also rarely be pigmented.


European Journal of Cancer and Clinical Oncology | 1989

Tolerability of the synthetic retinoid fenretinide® (HPR)☆

Alberto Costa; Winfred F. Malone; Marjorie Perloff; Fiamma Buranelli; Tiziana Campa; Giovanni Dossena; Andrea Magni; Maria A. Pizzichetta; Claudio Andreoli; Marcella Del Vecchio; Franca Formelli; Angelo Barbieri

Fenretinide, N-(4-hydroxyphenyl)retinamide (HPR), is a synthetic retinoid which has been proven effective in inducing cell differentiation and in inhibiting carcinogen induced mammary tumors in rodents. Because of its efficacy and low toxicity in animals, HPR has been proposed for chemopreventive evaluation in humans. Thus, a randomized trial has been conducted to select a dose which can be administered over a lengthy period of time and with acceptable toxicity. The retinoid was administered orally to patients already operated on for breast cancer in daily doses of 100, 200 and 300 mg for 6 months and subsequently at 200 mg for another 6 months. No acute toxicity was found. Dermatological toxicity was minimal and no liver function abnormalities were observed. Nausea and headaches were infrequent and always mild. Menstrual irregularities were recorded with similar frequency in the treatment and placebo groups and appeared to be more age related than drug dependent. After 6 months of treatment one of 25 patients taking 300 mg HPR daily experienced impaired night vision, confirmed by the electroretinogram, and resolved by interruption of treatment. Because the 300 mg daily dose is possibly associated with impaired dark adaptation, the recommended dose for chemoprevention trials of HPR is 200 mg per day.


British Journal of Dermatology | 2004

Clinically equivocal melanocytic skin lesions with features of regression: a dermoscopic-pathological study.

Iris Zalaudek; Giuseppe Argenziano; G. Ferrara; Hp Soyer; Rosamaria Corona; Francesco Sera; Lorenzo Cerroni; Andreina Carbone; A. Chiominto; Lorenza Cicale; G. De Rosa; A. Ferrari; R. Hofmann-Wellenhof; Josep Malvehy; Ketty Peris; Maria A. Pizzichetta; Susana Puig; Massimiliano Scalvenzi; Stefania Staibano; Vincenzo Ruocco

Background  Benign melanocytic skin lesions may be difficult to differentiate from melanoma both clinically and dermoscopically. One of the most confounding dermoscopic features, commonly seen in melanoma but in our experience also in melanocytic naevi, is represented by the so‐called blue–white structures (BWS).


Journal of Telemedicine and Telecare | 2000

Teledermoscopy - results of a multicentre study on 43 pigmented skin lesions

Domenico Piccolo; Josef Smolle; Giuseppe Argenziano; Ingrid H. Wolf; Ralph Braun; Lorenzo Cerroni; Angela Ferrari; Rainer Hofmann-Wellenhof; Robert O. Kenet; Fabio Magrini; Giampiero Mazzocchetti; Maria A. Pizzichetta; Wilhelm Stolz; Masaru Tanaka; Helmut Kerl; Sergio Chimenti; H. Peter Soyer

We performed a multicentre study to evaluate the agreement between the direct clinical diagnosis and the telediagnosis of 43 cutaneous pigmented lesions. Digital clinical and dermoscopic images of the 43 pigmented skin lesions (11 melanomas, 23 melanocytic naevi, three basal cell carcinomas, three lentigines, two seborrhoeic keratoses and one angiokeratoma) were sent by email to 11 colleagues (six dermatologists, two residents in dermatology, one oncologist, one specialist in internal medicine and one general practitioner) in 10 centres. These 11 colleagues had different degrees of experience in dermoscopy. With histopathology as the gold standard, an average of 85% of the telediagnoses were correct, with results varying from 77% to 95%, whereas face-to-face diagnosis by an expert dermatologist was correct in 91% of cases. The kappa value for all participants ranged from 0.35 to 0.87. The results confirm that teledermoscopy can be a reliable technique for the diagnosis of pigmented skin lesions but one that will depend on the expertise of the observer.


British Journal of Dermatology | 2006

Instrument-, age- and site-dependent variations of dermoscopic patterns of congenital melanocytic naevi: a multicentre study

Stefania Seidenari; Giovanni Pellacani; Alessandro Martella; Francesca Giusti; Giuseppe Argenziano; Pierluigi Buccini; Paolo Carli; Caterina Catricalà; V. De Giorgi; A. Ferrari; V. Ingordo; Am Manganoni; Ketty Peris; Domenico Piccolo; Maria A. Pizzichetta

Background  Recently, we identified and described dermoscopic aspects, present with a higher frequency in congenital melanocytic lesions with respect to acquired naevi. We also classified small‐ and medium‐sized congenital naevi (CN) into nine subtypes according to their macroscopic and dermoscopic aspects.


Dermatology | 2007

Dermoscopy Key Points: Recommendations from the International Dermoscopy Society

Jonathan Bowling; Giuseppe Argenziano; A Azenha; J Bandic; R Bergman; Andreas Blum; Horacio Cabo; A Di Stephani; James M. Grichnik; Allan C. Halpern; R Hofman-Wellenhof; Robert H. Johr; Harald Kittler; Alfred W. Kopf; Jürgen Kreusch; David Langford; J. Malvehy; Ashfaq A. Marghoob; Scott W. Menzies; Fezal Ozdemir; Ketty Peris; D Piccolo; Maria A. Pizzichetta; D Polsky; Susana Puig; Harold S. Rabinovitz; Pietro Rubegni; Toshiaki Saida; Massimiliano Scalvenzi; Stefania Seidenari

J. Bowling G. Argenziano A. Azenha J. Bandic R. Bergman A. Blum H. Cabo A. Di Stephani J. Grichnik A. Halpern R. Hofman-Wellenhof R. Johr H. Kittler A. Kopf J. Kreusch D. Langford J. Malvehy A. Marghoob S. Menzies F. Ozdemir K. Peris D. Piccolo M.A. Pizzichetta D. Polsky S. Puig H. Rabinovitz P. Rubegni T. Saida M. Scalvenzi S. Seidenari H.P. Soyer M. Tanaka I. Zalaudek R.P. Braun


JAMA Dermatology | 2013

Dermoscopic evaluation of nodular melanoma

Scott W. Menzies; Fergal J. Moloney; Karen Byth; Michelle Avramidis; Giuseppe Argenziano; Iris Zalaudek; Ralph P. Braun; Josep Malvehy; Susana Puig; Harold S. Rabinovitz; Margaret Oliviero; Horacio Cabo; Riccardo Bono; Maria A. Pizzichetta; Magdalena Claeson; Daniel C Gaffney; H. Peter Soyer; Ignazio Stanganelli; Richard A. Scolyer; Pascale Guitera; John W. Kelly; Olivia McCurdy; Alex Llambrich; Ashfaq A. Marghoob; Pedro Zaballos; Herbert Kirchesch; Domenico Piccolo; Jonathan Bowling; Luc Thomas; Karin Terstappen

IMPORTANCE Nodular melanoma (NM) is a rapidly progressing potentially lethal skin tumor for which early diagnosis is critical. OBJECTIVE To determine the dermoscopy features of NM. DESIGN Eighty-three cases of NM, 134 of invasive non-NM, 115 of nodular benign melanocytic tumors, and 135 of nodular nonmelanocytic tumors were scored for dermoscopy features using modified and previously described methods. Lesions were separated into amelanotic/hypomelanotic or pigmented to assess outcomes. SETTING Predominantly hospital-based clinics from 5 continents. MAIN OUTCOME MEASURES Sensitivity, specificity, and odds ratios for features/models for the diagnosis of melanoma. RESULTS Nodular melanoma occurred more frequently as amelanotic/hypomelanotic (37.3%) than did invasive non-NM (7.5%). Pigmented NM had a more frequent (compared with invasive non-NM; in descending order of odds ratio) symmetrical pigmentation pattern (5.8% vs 0.8%), large-diameter vessels, areas of homogeneous blue pigmentation, symmetrical shape, predominant peripheral vessels, blue-white veil, pink color, black color, and milky red/pink areas. Pigmented NM less frequently displayed an atypical broadened network, pigment network or pseudonetwork, multiple blue-gray dots, scarlike depigmentation, irregularly distributed and sized brown dots and globules, tan color, irregularly shaped depigmentation, and irregularly distributed and sized dots and globules of any color. The most important positive correlating features of pigmented NM vs nodular nonmelanoma were peripheral black dots/globules, multiple brown dots, irregular black dots/globules, blue-white veil, homogeneous blue pigmentation, 5 to 6 colors, and black color. A model to classify a lesion as melanocytic gave a high sensitivity (>98.0%) for both nodular pigmented and nonnodular pigmented melanoma but a lower sensitivity for amelanotic/hypomelanotic NM (84%). A method for diagnosing amelanotic/hypomelanotic malignant lesions (including basal cell carcinoma) gave a 93% sensitivity and 70% specificity for NM. CONCLUSIONS AND RELEVANCE When a progressively growing, symmetrically patterned melanocytic nodule is identified, NM needs to be excluded.


Cancer | 2001

Dermoscopic criteria for melanoma in situ are similar to those for early invasive melanoma

Maria A. Pizzichetta; Giuseppe Argenziano; Renato Talamini; Domenico Piccolo; Alessandro Gatti; Giusto Trevisan; Gian Mauro Sasso; Andrea Veronesi; Antonino Carbone; H. Peter Soyer

Dermoscopy is a noninvasive technique that increases the diagnostic accuracy of pigmented skin lesions, particularly improving the diagnosis of patients with cutaneous melanoma in situ (CMIS) and early invasive melanoma. To establish reliable and reproducible dermoscopic criteria for the diagnosis of CMIS, the authors conducted a retrospective clinical study of 37 patients with CMIS and 53 patients with invasive cutaneous melanomas (ICM).

Collaboration


Dive into the Maria A. Pizzichetta's collaboration.

Top Co-Authors

Avatar

Giuseppe Argenziano

Seconda Università degli Studi di Napoli

View shared research outputs
Top Co-Authors

Avatar

H. Peter Soyer

University of Queensland

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Renato Talamini

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Andrea Veronesi

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Scott W. Menzies

Royal Prince Alfred Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge